Valeant Pharmaceuticals reported $10.9 million in net income for the quarter ended June 30, up from a net loss of $21.6 million during the same period last year, according to a company news release. The company also announced it finalized its acquisition of Bausch + Lomb as of Aug. 5, including issuing 27.1 million common shares to raise $9.6 billion in support of the purchase.